Pharmacokinetics of alectinib and its metabolite M4 in a patient with advanced lung adenocarcinoma undergoing hemodialysis: A case report

Abstract This study presents the first detailed pharmacokinetic data of alectinib and its metabolite M4 in a patient with anaplastic lymphoma kinase (ALK)‐rearranged lung adenocarcinoma undergoing hemodialysis. When the patient was administered a daily 300 mg bid dose of alectinib, the maximal obser...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Ji Eun Park, Young‐Ran Yoon, Chang Ho Kim, Jaehee Lee
Formato: Artigo
Lenguaje:Inglês
Publicado: Wiley 2022-04-01
Colección:Thoracic Cancer
Materias:
alectinib
ALK rearrangement
lung cancer
M4
pharmacokinetics
Acceso en línea:https://doi.org/10.1111/1759-7714.14357
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares